title: [Clinical and Pathological Analysis of 9 Patients with Primary Breast Diffuse Large B-cell Lymphoma].
abstract: OBJECTIVE
  To explore the clinical features, diagnosis and treatment of primary breast diffuse large B- cell lymphoma (PBDLBCL).
  
  
  METHODS
  Clinical records of 9 PBDLBCL patients treated in Department of Hematology of Yijishan Hospital Affiliated to Wannan Medical College from August 2001 to January 2014 were analyzed retrospectively.
  
  
  RESULTS
  All of the 9 patients were female, with an average age of 48 years (range 28 to 75), 8 cases had unilateral breast tumors and 1 case had bilateral. According to the Ann Arbor stage standard, 2 cases were of stage IE and 7 were IIE. None of them was concurrent with B symptoms; 6 cases had IPI (International prognostic Index) score 0 and 3 had score 1. 2 cases belonged to germinal center B cells type (GCB) and 7 belonged to non-GCB. Double-Hit lymphomas were presented in 3 cases. Out of 9 cases, 3 cases were diagnosed by using tubular needle biopsy, 5 cases were diagnosed by using resection of breast mass, and 1 case was diagnosed by using modified radical mastectomy. 1 case received radical mastectomy, 1 case received unilateral breast removal, 1 case gave up, 1 case received mass excision with chemotherapy and radiotherapy, 5 cases received mass excision with chemotherapy and 1 case received central prophylaxis. A complete response (CR) was observed in 6 cases after first-line chemotherapy. The median follow-up time was 18 months (range 0.1 to 150), 3 cases relapsed and 5 cases died.
  
  
  CONCLUSIONS
  PBDLBCL mostly occurs in female. The main pathological type is non-GCB coupled with Double-Hit lymphoma. Tubular needle biopsy offers benifit in the diagnosis of PBL, R-CHOP or R-CHOP combined with chemotherapy/radiotherapy produce best outcome among all the treatments. Intrathecal injection of chemotherapy drugs may help to prevent recurrence of PBL central.
authors.affiliation: Department of Hematology, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
authors.forename: Zhong-Ling
authors.initials: ZL
authors.lastname: Wei
authors.affiliation: Department of Hematology, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
authors.forename: Dong-Ping
authors.initials: DP
authors.lastname: Huang
authors.affiliation: Department of Hematology, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
authors.forename: Gui-Ping
authors.initials: GP
authors.lastname: Su
authors.affiliation: Department of Hematology, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
authors.forename: Xing-Hong
authors.initials: XH
authors.lastname: Wang
authors.affiliation: Department of Hematology, Yijishan Hospital, Wuhu 241000, Anhui Province, China.
authors.forename: Yi-Zhi
authors.initials: YZ
authors.lastname: Jiang
authors.affiliation: Department of Hematology, Yijishan Hospital, Wuhu 241000, Anhui Province, China. E-mail: 13975531760@163.com.
authors.forename: Lai-Quan
authors.initials: LQ
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011241:Prednisone; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine
chemical_list: D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone